Table 3 Influencing factors on survival time and time to progression

ILD Subtype

IPF

(n = 152)

5.8

(0.6–14.5)

18.9

(1.1–47.54)

iNSIP

(n = 42)

9.2

(0.4–18.3)

0.83

[0.47, 1.48]

0.535

14.6

(0.9–32.69)

1.08

[0.7, 1.67]

0.728

COP

(n = 25)

n.e.

(0.7–3.2)

0.53

[0.21, 1.31]

0.171

40.1

(1.7–42.02)

0.5

[0.27, 0.9]

0.021

uILD

(n = 34)

5.6

(0.2–5.6)

0.97

[0.54, 1.75]

0.923

21.6

(0.1–44.94)

0.8

[0.5, 1.28]

0.351

Sarcoidosis

(n = 160)

n.e.

(1.2–34.4)

0.33

[0.18, 0.63]

< 0.001

n.e.

(0.2–46.59)

0.31

[0.22, 0.43]

< 0.001

HP

(n = 58)

16.0

(1.6–22.6)

0.3

[0.17, 0.53]

< 0.001

32.4

(4.8–40.28)

0.6

[0.4, 0.89]

0.011

CTD-ILD

(n = 43)

15.5

(0.6–15.5)

0.33

[0.18, 0.6

< 0.001

22.2

(3.0–36.47)

0.78

[0.5, 1.21]

0.262

DI-ILD

(n = 16)

6.0

(0.2–6.0)

1.41

[0.68, 2.93]

0.358

23.7

(0.5–43.43)

0.75

[0.41, 1.4]

0.372

N = 601

Survival time (years)

Median (range)

HR

[95% CI]

p value

(Wald test)

ILD-GAP Index

II vs. I

4.95

[3.02, 8.11]

< 0.001

III vs. I

9.06

[5.58, 14.71]

< 0.001

No PFT vs. I

4.34

[2.13, 8.83]

< 0.001

AE-ILD

AE-ILD

(n = 124)

7.3

(0.1–34.4)

0.39

[0.29, 0.53]

< 0.001

No AE-ILD

(n = 477)

19.6

(0.3–19.6)

LTOT

LTOT

(n = 164)

6.1

(0.1–34.4)

0.26

[0.19, 0.36]

< 0.001

No LTOT

(n = 437)

n.e.

(0.2–19.1)